Cargando…

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES

Detalles Bibliográficos
Autores principales:	Atluri, Himachandana, Patel, Keyur, Routbort, Mark, Oran, Betul, Issa, Ghayas, Short, Nicholas, Daver, Naval, Kadia, Tapan, Ravandi, Farhad, E. Champlin, Richard, J. Shpall, Elizabeth, Pierce, Sherry, Kanagal-Shamanna, Rashmi, Young Ok, Chi, Tang, Guilin, Wang, Sa, Luthra, Rajyalakshmi, Lasrey, Audrey, Nadorp, Bettina, Chroni, Antonia, Eisfeld, Ann-Kathrin, Aifantis, Ioannis, Medeiros, L. Jeffrey, Dinardo, Courtney, Loghavi, Sanam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429204/ http://dx.doi.org/10.1097/01.HS9.0000969236.15137.e3

Ejemplares similares

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
por: Alotaibi, Ahmad S., et al.
Publicado: (2020)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
por: Bannon, Sarah A., et al.
Publicado: (2021)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
por: Short, Nicholas J., et al.
Publicado: (2023)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
por: Short, Nicholas J., et al.
Publicado: (2022)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

Hematologic malignancies and Li–Fraumeni syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2019)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
por: Reville, Patrick K., et al.
Publicado: (2021)

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
por: Short, Nicholas J., et al.
Publicado: (2022)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9f056ju59h11o8bubkh2d4fur9